2,056 results match your criteria Expert Review of Vaccines[Journal]


Environmental factors which can affect the burden of pneumococcal disease and the immune response to pneumococcal vaccines: the need for more precisely delineated vaccine recommendations.

Expert Rev Vaccines 2019 Apr 18. Epub 2019 Apr 18.

b Division of Infectious Diseases, Department of Internal Medicine , Guro Hospital, Korea University College of Medicine , Seoul , Republic of Korea.

Introduction: Precision medicine describes the customization of healthcare tailored to the individual patient. Generally, vaccines are considered as public health tools rather than from the individual patient perspective. However, adult vaccination programs in particular should consider many different factors, at the individual level and also from societal, cultural and country-specific perspectives. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1607303DOI Listing

Prophylactic and therapeutic strategies for Epstein-Barr Virus-associated diseases: emerging strategies for clinical development.

Expert Rev Vaccines 2019 Apr 15. Epub 2019 Apr 15.

a QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Tumour Immunology Laboratory, Department of Immunology , QIMR Berghofer Medical Research Institute , Brisbane , Queensland , Australia.

Introduction: Epstein-Barr virus (EBV) infects more than 95% of the world's population and is associated with infectious mononucleosis as well as a number of cancers in various geographical locations. Despite its significant health burden, no licenced prophylactic or therapeutic vaccines are available. Areas covered: Over the last two decades, our understanding of the role of EBV infection in the pathogenesis and immune regulation of EBV-associated diseases has provided new lines of research to conceptualize various novel prophylactic and therapeutic approaches to control EBV-associated disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1605906DOI Listing

Update on vaccination of preterm infants: a systematic review about safety and efficacy/effectiveness. Proposal for a position statement by Italian Society of Pediatric Allergology and Immunology jointly with the Italian Society of Neonatology.

Expert Rev Vaccines 2019 Apr 5. Epub 2019 Apr 5.

c Pediatric Clinic, IRCCS Policlinico "S. Matteo" Foundation , University of Pavia , Pavia , Italy .

Introduction: Preterm infants (PIs) are at increased risk of vaccine preventable diseases (VPDs). However delayed vaccination start and low vaccine coverage are still reported. Areas covered: This systematic review includes 37 articles on preterm vaccination published in 2008-2018 in PubMed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1604230DOI Listing
April 2019
2 Reads

Prospects of acne vaccines targeting secreted virulence factors of Cutibacterium acnes.

Expert Rev Vaccines 2019 Mar 28:1-5. Epub 2019 Mar 28.

a Department of Life Sciences , National Central University , Taoyuan , Taiwan.

Introduction: Acne vulgaris afflicts many people, and despite the multitude of the anti-acne products on the market, there is still no effective treatment that can prevent and cure this disease. The severity of acne vulgaris is highly associated with the inflammatory response to Propionibacterium acnes (P. acnes) now referred to as Cutibacterium acnes (C. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1593830DOI Listing
March 2019
2 Reads
4.210 Impact Factor

Seasonal influenza vaccination and absenteeism in health-care workers in two subsequent influenza seasons (2016/17 and 2017/18) in an Italian pediatric hospital.

Expert Rev Vaccines 2019 Apr 28;18(4):411-418. Epub 2019 Mar 28.

a Occupational Medicine, Bambino Gesù Children's Hospital , IRCCS , Rome , Italy.

Background: Seasonal influenza in Health-Care Workers (HCWs) is a topic of growing interest in public health for its organizational implications. The study aims at measuring absenteeism due to influenza in HCWs of an Italian pediatric hospital.

Research Design And Methods: A retrospective observational study on absenteeism for influenza and influenza-like illness was carried out on all hospital HCWs. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1586541DOI Listing
April 2019
4 Reads

In utero exposure to biologic disease-modifying anti-rheumatic drugs and effects to the infant: infectious complications, vaccine response, and safety of live vaccine administration.

Expert Rev Vaccines 2019 Mar 27:1-10. Epub 2019 Mar 27.

a Infection Management and Prevention Service, Queensland Children's Hospital , University of Queensland , Brisbane , Australia.

Introduction: Biologic disease-modifying anti-rheumatic drugs (bDMARDS) are increasingly used in clinical practice for a variety of conditions. Due to concerns surrounding persistence of drug levels and resulting immunosuppression, current case reports recommend against live vaccine administration in the first year of life for an infant exposed to perinatal bDMARDS. As a result, this significantly impacts receipt of rotavirus vaccination, a vaccine recommended in many countries' national immunization program. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1599286DOI Listing

Designing tuberculosis vaccine efficacy trials - lessons from recent studies.

Authors:
Ann M Ginsberg

Expert Rev Vaccines 2019 Mar 20:1-10. Epub 2019 Mar 20.

a Clinical Development , International AIDS Vaccine Initiative , New York , NY , USA.

Introduction: Tuberculosis (TB) is the leading infectious killer globally and new TB vaccines will be crucial to ending the epidemic. Since the introduction in 1921 of the only currently licensed TB vaccine, BCG, very few novel vaccine candidates or strategies have advanced into clinical efficacy trials. Areas covered: Recently, however, two TB vaccine efficacy trials with novel designs have reported positive results and are now driving new momentum in the field. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1593143DOI Listing

The burden of pertussis in older adults: what is the role of vaccination? A systematic literature review.

Expert Rev Vaccines 2019 Mar 25:1-17. Epub 2019 Mar 25.

a GSK , Wavre , Belgium.

Introduction: Pertussis (whooping cough) is a vaccine-preventable disease; however, neither natural- nor vaccine-induced protection is life-long. Although generally not severe in adults, pertussis can be associated with complications in patients with chronic conditions such as asthma or chronic obstructive pulmonary disease, and can be readily transmitted to more vulnerable populations, including neonates before they complete their primary vaccination. Furthermore, as the global population ages, the health and economic burden of the disease is expected to rise. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1588727DOI Listing
March 2019
5 Reads
4.210 Impact Factor

A vaccine targeting blood clot formation: what is the potential?

Expert Rev Vaccines 2019 Mar 19:1-3. Epub 2019 Mar 19.

a Department of Health Development and Medicine , Osaka University Graduate School of Medicine , Suita , Osaka , Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1588114DOI Listing

Management of meningococcal outbreaks: are we using the same language? Comparison of the public health policies between high-income countries with low incidence of meningococcal disease.

Expert Rev Vaccines 2019 Mar 15:1-16. Epub 2019 Mar 15.

e Department of Biomedical and Neuromotor Sciences , University of Bologna , Bologna , Italy.

Background: Invasive meningococcal disease (IMD) in high-income countries usually occurs sporadically with low incidence and occasionally as small clusters or outbreaks. The WHO guidelines (GLs) for IMD outbreak applies only to African countries with high endemic incidence. Several high-income countries developed their own GLs on IMD outbreak, and we compare their terminology, classification, definitions, and public health interventions. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1595595DOI Listing
March 2019
2 Reads

Burden of varicella in the Asia-Pacific region: a systematic literature review.

Expert Rev Vaccines 2019 Mar 14:1-19. Epub 2019 Mar 14.

h Center for Observational and Real-World Evidence , Merck & Co., Inc ., Kenilworth , NJ , USA.

Introduction: Varicella is a highly contagious infection that can lead to serious complications, particularly in high-risk groups; however, it is vaccine preventable. Disease awareness and understanding of the disease burden can strongly influence vaccine coverage. This review provides insight into the current epidemiology and the importance of varicella from both public health and economic perspectives across the Asia-Pacific (APAC) region. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1594781DOI Listing
March 2019
6 Reads

Prevalence and dynamics of missed opportunities for vaccination among children in Africa: applying systems thinking in a systematic review and meta-analysis of observational studies.

Expert Rev Vaccines 2019 Mar 1:1-12. Epub 2019 Mar 1.

a Cochrane South Africa , South African Medical Research Council , Tygerberg , South Africa.

Objective: To estimate the prevalence of missed opportunities for vaccination (MOV) among children aged 0-23 months attending health-care facilities in Africa and explore the factors responsible for MOV using systems thinking.

Research Design And Methods: We conducted a systematic review and meta-analysis of studies reporting the proportion MOVs. Five electronic databases were searched. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1588728DOI Listing
March 2019
10 Reads
4.210 Impact Factor

Introduction of a second MenB vaccine into Europe - needs and opportunities for public health.

Expert Rev Vaccines 2019 Mar 1;18(3):225-239. Epub 2019 Mar 1.

c Centre for Epidemiology and Microbiology - National Institute of Public Health , Prague , Czech Republic.

Introduction: Invasive meningococcal disease (IMD) can be devastating; it is associated with high case fatality rates and long-term sequelae among many survivors. Five serogroups (A, B, C, W, and Y) cause nearly all IMD cases worldwide, and serogroup B (MenB) is the most prevalent in Europe. The European Medicines Agency approved the use of MenB-fHbp (Trumenba®; Pfizer Ltd, Sandwich, UK) in individuals ≥10 years of age for the prevention of MenB IMD in May 2017. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1578217DOI Listing
March 2019
3 Reads

Burden of varicella in Central and Eastern Europe: findings from a systematic literature review.

Expert Rev Vaccines 2019 Mar 27;18(3):281-293. Epub 2019 Feb 27.

o Center for Observational and Real-World Evidence (CORE) , Merck & Co., Inc ., Kenilworth , NJ , USA.

Introduction: Vaccination against varicella rapidly reduces disease incidence, resulting in reductions in both individual burden and societal costs. Despite these benefits, there is no standardization of varicella immunization policies in Europe, including countries in Central and Eastern Europe (CEE). Areas covered: This systematic literature review identified publications on the epidemiology of varicella, its associated health and economic burden, and vaccination strategies within the CEE region, defined as Albania, Bosnia-Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Serbia, Slovakia, and Slovenia. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1573145DOI Listing
March 2019
8 Reads

Subcutaneous nodules: an important adverse event following immunization.

Expert Rev Vaccines 2019 Apr 11;18(4):405-410. Epub 2019 Mar 11.

c Population Allergy Research Group and Melbourne Children's Trial Centre , Murdoch Children's Research Institute , Melbourne , Australia.

Introduction: Subcutaneous nodules are a rare adverse event following immunization (AEFI). Reported cases have frequently been associated with aluminum-containing vaccines. Despite the development of a consensus definition of a subcutaneous nodule from the Brighton Collaboration in 2004, there continues to be variation in definitions used in published literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1586540DOI Listing
April 2019
8 Reads

Clinical experience with the inactivated hepatitis A vaccine, Avaxim 80U Pediatric.

Expert Rev Vaccines 2019 Mar 26;18(3):209-223. Epub 2019 Feb 26.

a Global Medical Affairs , Sanofi Pasteur , Lyon , France.

Introduction: Hepatitis A, caused by hepatitis A virus (HAV), is primarily transmitted via the fecal/oral route either through ingestion of contaminated food and water or through direct contact with an infectious person. Prevalence of hepatitis A is strongly correlated with socioeconomic factors, decreasing with increased socio-economic development, access to clean water and sanitation. Vaccination against HAV should be part of a comprehensive plan for the prevention and control of viral hepatitis, either as part of regular childhood immunization programs or with other recommended vaccines for travelers. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1580578DOI Listing
March 2019
11 Reads

Deciphering protective immunity against tuberculosis: implications for vaccine development.

Expert Rev Vaccines 2019 Apr 4;18(4):353-364. Epub 2019 Mar 4.

a Tuberculosis Research Program Centenary Institute , The University of Sydney , Camperdown , NSW , Australia.

Introduction: The development of more effective tuberculosis (TB) vaccines is essential for the global control of TB. Recently, there have been major advances in the field, but an important hindrance remains the lack of correlates of protection against TB. This requires each vaccine candidate to undergo clinical efficacy trials based on data from animal protection studies, but the results from animal models do not necessarily predict efficacy in humans. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1585246DOI Listing

Recombinant influenza A viruses as vaccine vectors.

Expert Rev Vaccines 2019 Apr 4;18(4):379-392. Epub 2019 Mar 4.

a Research Center for Emerging Infections and Zoonoses (RIZ) , University of Veterinary Medicine Hannover (TiHo) , Hannover , Germany.

Introduction: Various viruses, including poxviruses, adenoviruses and vesicular stomatitis virus, have been considered as vaccine vectors for the delivery of antigens of interest in the development of vaccines against newly emerging pathogens. Areas covered: Here, we review results that have been obtained with influenza A viruses (IAV) as vaccine vectors. With the advent of reverse genetics technology, IAV-based recombinant vaccine candidates have been constructed that induce protective immunity to a variety of different pathogens of interest, including West Nile virus, Plasmodium falciparum and respiratory syncytial virus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1582338DOI Listing
April 2019
3 Reads

Experimental models used in evaluating anti-tuberculosis vaccines: the latest advances in the field.

Expert Rev Vaccines 2019 Apr 27;18(4):365-377. Epub 2019 Feb 27.

b Basic Sciences Department, School of Medicine and Health Sciences , Universidad del Rosario , Bogotá , Colombia.

Introduction: Tuberculosis is an infectious disease which is caused by bacilli from the M. tuberculosis complex. The Mycobacterium bovis Bacillus Calmette-Guérin vaccine is currently available as a prophylactic tool for preventing the disease; it has been shown to be efficient in preventing disseminated forms of tuberculosis during early ages; however, its efficiency is limited in areas where individuals have had prior exposure to environmental mycobacteria, and its efficacy decreases with a host's age. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1583558DOI Listing
April 2019
3 Reads

HPV vaccination in Japan: what is happening in Japan?

Expert Rev Vaccines 2019 Apr 22;18(4):323-325. Epub 2019 Feb 22.

a Department of Gynecology, Tama-Hokubu Medical Center , Tokyo Metropolitan Health and Medical Treatment Corporation , Higashimurayama, Tokyo , Japan.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1584040DOI Listing
April 2019
10 Reads

Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States.

Expert Rev Vaccines 2019 Apr 20;18(4):327-341. Epub 2019 Mar 20.

a Department of Health Policy , Vanderbilt University , Nashville , TN , USA.

Introduction: Pneumonia is one of the leading causes of morbidity and mortality among children and older adults. Pneumococcal conjugate vaccines (PCVs) were introduced into the US routine infant vaccination schedule leading to substantial reductions of invasive pneumococcal diseases (IPD). PCV introduction also led to reductions in all-cause pneumonia among US children, though the indirect impact of PCVs on pneumonia in adults is difficult to quantify, especially due to the recent US recommendation for direct PCV use in older adults. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1582337DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443450PMC
April 2019
3 Reads

Optimizing the timing of 4CMenB vaccination in adolescents and young adults based on immune persistence and booster response data.

Expert Rev Vaccines 2019 Apr 22;18(4):343-352. Epub 2019 Mar 22.

c GSK , Marburg , Germany.

Introduction: Meningococcal disease has an incidence peak spread over several years during adolescence and young adulthood in the United States. Meningococcal serogroup B (MenB) vaccines have been introduced relatively recently and may help protect individuals in these age groups. Currently there is insufficient long-term experience to determine the duration of disease protection after any MenB vaccine. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1580579DOI Listing
April 2019
4 Reads

Post-hoc analysis from phase III trials of human papillomavirus vaccines: considerations on impact on non-vaccine types.

Expert Rev Vaccines 2019 Mar 4;18(3):309-322. Epub 2019 Mar 4.

d Translational Science , GSK , Rixensart , Belgium.

Background: Substantial heterogeneity has been reported in efficacy against high-grade cervical intraepithelial neoplasia (CIN) irrespective of HPV type in phase III results for bivalent and quadrivalent human papillomavirus virus (HPV) vaccines (AS04-HPV and qHPV). Real-world data recently confirmed a very high overall impact of AS04-HPV, supporting the validity of the observed heterogeneity. To explore the reasons for heterogeneous efficacy, we assessed vaccine impact on high-grade lesions not caused by vaccine types. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1579647DOI Listing
March 2019
3 Reads

The prevention of severe pertussis and pertussis deaths in young infants.

Authors:
James D Cherry

Expert Rev Vaccines 2019 Mar 22;18(3):205-208. Epub 2019 Feb 22.

a Department of Pediatrics , David Geffen School of Medicine at UCLA , Los Angeles , CA , USA.

Introduction: Today, in the developed world, virtually all deaths due to Bordetella pertussis illnesses occur in young infants. Areas Covered: Pertussis in young infants is characterized by an afebrile cough illness with coryza, apnea, seizures, cyanosis, and emesis. Severe illness is associated with high leukocyte and lymphocyte counts, rapid respiratory and cardiac rates and pneumonia. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1581065DOI Listing
March 2019
9 Reads

Human challenge models: tools to accelerate the development of malaria vaccines.

Expert Rev Vaccines 2019 Mar 27;18(3):241-251. Epub 2019 Feb 27.

a Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine , James Cook University , Cairns , Australia.

Introduction: Malaria challenge models, where healthy human volunteers are intentionally infected with Plasmodium species parasites under controlled conditions, can be undertaken in several well-defined ways. These challenge models enable evaluation of the kinetics of parasite growth and clearance, host-pathogen interactions and the host immune response. They can facilitate discovery of candidate diagnostic biomarkers and novel vaccine targets. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1580577DOI Listing
March 2019
15 Reads

Immunological basis for enhanced immunity of nanoparticle vaccines.

Expert Rev Vaccines 2019 Mar 14;18(3):269-280. Epub 2019 Feb 14.

a Department of Microbiology and Immunology , University of Melbourne, at The Peter Doherty Institute for Infection and Immunity , Melbourne , Australia.

Introduction: Immunization has been a remarkably successful public health intervention; however, new approaches to vaccine design are essential to counter existing and emerging infectious diseases which have defied traditional vaccination efforts to date. Nanoparticles (ordered structures with dimensions in the range of 1-1000 nm) have great potential to supplement traditional vaccines based upon pathogen subunits, or killed or attenuated microorganisms, as exemplified by the successful licensure of virus-like particle vaccines for human papillomavirus and hepatitis B. However, the immunological mechanisms that underpin the potent immunity of nanoparticle vaccines are poorly defined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1578216DOI Listing
March 2019
2 Reads

The role of systems biology approaches in determining molecular signatures for the development of more effective vaccines.

Expert Rev Vaccines 2019 Mar 11;18(3):253-267. Epub 2019 Feb 11.

a Mayo Vaccine Research Group , Mayo Clinic , Rochester , MN , USA.

Introduction: Emerging infectious diseases are a major threat to public health, and while vaccines have proven to be one of the most effective preventive measures for infectious diseases, we still do not have safe and effective vaccines against many human pathogens, and emerging diseases continually pose new threats. The purpose of this review is to discuss how the creation of vaccines for these new threats has been hindered by limitations in the current approach to vaccine development. Recent advances in high-throughput technologies have enabled scientists to apply systems biology approaches to collect and integrate increasingly large datasets that capture comprehensive biological changes induced by vaccines, and then decipher the complex immune response to those vaccines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1575208DOI Listing

Introducing new vaccines in low- and middle-income countries: challenges and approaches.

Expert Rev Vaccines 2019 02 11;18(2):119-131. Epub 2019 Feb 11.

a Research and Development , GSK , Wavre , Belgium.

Introduction: The number of new vaccine introductions (NVIs) in low and middle-income countries (LMICs) has markedly increased since 2010, raising challenges to often overstretched and underfunded health care systems.

Areas Covered: We present an overview of some of these challenges, focusing on programmatic decisions, delivery strategy, information and communication, pharmacovigilance and post-licensure evaluation. We also highlight field-based initiatives that may facilitate NVI. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1574224DOI Listing
February 2019
7 Reads

Immunogenicity of high-dose trivalent inactivated influenza vaccine: a systematic review and meta-analysis.

Expert Rev Vaccines 2019 Mar 13;18(3):295-308. Epub 2019 Feb 13.

a Sanofi Pasteur , Swiftwater , PA , USA.

Introduction: High-dose trivalent, inactivated, split-virus influenza vaccine (IIV3-HD) has been available in the US since 2009 for adults aged ≥ 65 years. To better understand how IIV3-HD provides improved protection against influenza, we systematically reviewed clinical studies comparing immune responses to IIV3-HD and standard-dose trivalent vaccine (IIV3-SD). Areas covered: The primary objective was to determine the relative hemagglutination inhibition (HAI) antibody response of IIV3-HD vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1575734DOI Listing

Aiming at the heart: the capsid protein of dengue virus as a vaccine candidate.

Expert Rev Vaccines 2019 02 11;18(2):161-173. Epub 2019 Feb 11.

a Vaccine Department , Center for Genetic Engineering and Biotechnology (CIGB) , Havana , Cuba.

Introduction: Dengue fever remains as a health problem worldwide. Although Dengvaxia®, was registered in several countries, the results after the immunization of people suggest an increase of risk in non-immune persons and children younger than 9 years old. No other vaccine is registered so far, thus the development of a safe and effective vaccine continues to be a priority for the WHO and the scientific community. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1574575DOI Listing
February 2019
4 Reads

Eradication of human papillomavirus and elimination of HPV-related diseases - scientific basis for global public health policies.

Expert Rev Vaccines 2019 02 7;18(2):153-160. Epub 2019 Feb 7.

a Department of Laboratory Medicine , Karolinska Institute , Stockholm , Sweden.

Introduction: Infections with oncogenic human papillomaviruses (HPV) globally cause about 9% of cancers in females and 1% of cancers in males. HPV disease burden can be effectively controlled by prophylactic HPV-vaccination provided it has high impact.

Areas Covered: A unique series of biobank-based and health registry-based studies that exploit randomized intervention cohorts has provided data on population-level safety of HPV vaccination, duration of vaccine-induced protection and impact of gender-neutral HPV vaccination, providing a scientific basis for policies to eradicate oncogenic HPV types and associated diseases worldwide. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1568876DOI Listing
February 2019
12 Reads

Malaria vaccines in the eradication era: current status and future perspectives.

Expert Rev Vaccines 2019 02 24;18(2):133-151. Epub 2019 Jan 24.

b School of Health and Biomedical Sciences , RMIT University , Bundoora , Australia.

Introduction: The challenge to eradicate malaria is an enormous task that will not be achieved by current control measures, thus an efficacious and long-lasting malaria vaccine is required. The licensing of RTS, S/AS01 is a step forward in providing some protection, but a malaria vaccine that protects across multiple transmission seasons is still needed. To achieve this, inducing beneficial immune responses while minimising deleterious non-targeted effects will be essential. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1561289DOI Listing
February 2019
2 Reads

Measles-vectored vaccine approaches against viral infections: a focus on Chikungunya.

Expert Rev Vaccines 2019 Apr 11;18(4):393-403. Epub 2019 Mar 11.

b Viral Genomics and Vaccination Unit, UMR-3569 CNRS, Department of Virology , Institut Pasteur , Paris , France.

Introduction: The large global burden of viral infections and especially the rapidly spreading vector-borne diseases and other emerging viral diseases show the need for new approaches in vaccine development. Several new vaccine technology platforms have been developed and are under evaluation. Areas covered: This article discusses the measles vector platform technology derived from the safe and highly efficacious measles virus vaccine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1562908DOI Listing
April 2019
2 Reads

Next generation designer virus-like particle vaccines for dengue.

Expert Rev Vaccines 2019 02 17;18(2):105-117. Epub 2019 Jan 17.

a Recombinant Gene Products Group, Molecular Medicine Division , International Centre for Genetic Engineering & Biotechnology , New Delhi , India.

Introduction: A safe and efficacious vaccine for dengue continues to be an unmet public health need. The recent licensing of a dengue vaccine (Dengvaxia) developed by Sanofi has brought to the fore the safety issue of vaccine-induced infection enhancement.

Areas Covered: This article focuses on two new yeast-produced tetravalent dengue envelope domain III-displaying virus-like particulate vaccine candidates reported in early 2018 and reviews the rationale underlying their design, and pre-clinical data which suggest that these may offer promising alternate options. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1562909DOI Listing
February 2019
15 Reads

Enhancing uptake of influenza maternal vaccine.

Expert Rev Vaccines 2019 02 28;18(2):191-204. Epub 2019 Jan 28.

a Hubert Department of Global Health, Rollins School of Public Health , Emory University , Atlanta , GA , USA.

Introduction: Influenza vaccination during pregnancy can offer many benefits to both mother and infant. Despite recommendations from the Advisory Committee on Immunization Practices, vaccine coverage rates among pregnant women during pregnancy are below 40% in the United States. There is a need for a greater understanding of what interventions can improve vaccine uptake among pregnant women. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1562907DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378696PMC
February 2019
25 Reads

Current perspectives in assessing humoral immunity after measles vaccination.

Expert Rev Vaccines 2019 01 26;18(1):75-87. Epub 2018 Dec 26.

a Mayo Clinic Vaccine Research Group , Mayo Clinic , Rochester , MN , USA.

Introduction: Repeated measles outbreaks in countries with relatively high vaccine coverage are mainly due to failure to vaccinate and importation; however, cases in immunized individuals exist raising questions about suboptimal measles vaccine-induced humoral immunity and/or waning immunity in a low measles-exposure environment.

Areas Covered: The plaque reduction neutralization measurement of functional measles-specific antibodies correlates with protection is the gold standard in measles serology, but it does not assess cellular-immune or other parameters that may be associated with durable and/or protective immunity after vaccination. Additional correlates of protection and long-term immunity and new determinants/signatures of vaccine responsiveness such as specific CD46 and IFI44L genetic variants associated with neutralizing antibody titers after measles vaccination are under investigation. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1559063DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413513PMC
January 2019
16 Reads

Current landscape of nonmedical vaccination exemptions in the United States: impact of policy changes.

Expert Rev Vaccines 2019 02 4;18(2):175-190. Epub 2019 Jan 4.

a Hubert Department of Global Health, Rollins School of Public Health , Emory University , Atlanta , GA , USA.

Introduction: In the United States, high childhood vaccination coverage has reduced the morbidity and mortality due to vaccine-preventable diseases. The success of vaccination programs in achieving this high coverage is due, in part, to vaccination mandates for school entry. All states have such mandates, but there is heterogeneity across the states in the allowance of non-medical exemptions (e. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1562344DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386772PMC
February 2019
18 Reads

The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations.

Expert Rev Vaccines 2019 01 27;18(1):15-30. Epub 2018 Dec 27.

p National Institute for Communicable Disease Control and Prevention , Chinese Centre for Disease Control and Prevention , Beijing , China.

Introduction: The 2018 Global Meningococcal Initiative (GMI) meeting focused on evolving invasive meningococcal disease (IMD) epidemiology, surveillance, and protection strategies worldwide, with emphasis on emerging antibiotic resistance and protection of high-risk populations. The GMI is comprised of a multidisciplinary group of scientists and clinicians representing institutions from several continents.

Areas Covered: Given that the incidence and prevalence of IMD continually varies both geographically and temporally, and surveillance systems differ worldwide, the true burden of IMD remains unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1557520DOI Listing
January 2019
19 Reads

Accelerating HIV vaccine development using non-human primate models.

Expert Rev Vaccines 2019 01 17;18(1):61-73. Epub 2018 Dec 17.

a Vaccine Branch, Center for Cancer Research , National Cancer Institute, National Institutes of Health , Bethesda , MD , USA.

Introduction: The search for a preventative HIV vaccine is ongoing after three decades of research. Contributions of non-human primate (NHP) models to this research are irrefutable, however interpreting data obtained for translation to humans has been problematic. As knowledge concerning NHP models has accumulated, their utility and value in assessing immunogenicity and efficacy of novel vaccines have become apparent. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1557521DOI Listing
January 2019
18 Reads

HPV vaccines and lupus: current approaches towards preventing adverse immune cross-reactivity.

Expert Rev Vaccines 2019 01 16;18(1):31-42. Epub 2018 Dec 16.

c Department of Medicine B and Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Sackler Faculty of Medicine , Tel-Aviv University , Tel-Aviv , Israel.

Introduction: If not properly treated, human papillomavirus (HPV) infection may evolve from a common sexually transmitted disease to genital warts and cervical cancer. Various prophylactic HPV vaccines (HPVv), approved to reduce the incidence of the infection, have been found to be effective and safe; however, accounts of post-vaccination autoimmune phenomena, including systemic lupus erythematosus (SLE), have been reported in genetically susceptible individuals.

Areas Covered: Infectious agents play a role in breaking the immunologic tolerance to self-antigens, resulting in autoimmune events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1557519DOI Listing
January 2019
5 Reads

Serotype distribution, antibiotic resistance pattern, and multilocus sequence types of invasive Streptococcus pneumoniae isolates in two tertiary pediatric hospitals in Beijing prior to PCV13 availability.

Expert Rev Vaccines 2019 01 12;18(1):89-94. Epub 2018 Dec 12.

a Beijing Key Laboratory of Pediatric Respiratory Infection Diseases, Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases , National Key Discipline of Pediatrics (Capital Medical University), Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health , Beijing , China.

Background: Invasive pneumococcal disease (IPD) is a serious threat to children worldwide. This study reported the serotype distribution, antibiotic resistance pattern, and multilocus sequence types of 111 IPD strains isolated from children less than 14 years old in two tertiary pediatric centers in Beijing during the years 2012-2017.

Methods: Serotypes were determined using Quellung reaction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1557523DOI Listing
January 2019
4 Reads
4.210 Impact Factor

The 5th virus-like particle and nano-particle vaccines (VLPNPV) conference.

Expert Rev Vaccines 2019 01 13;18(1):1-3. Epub 2018 Dec 13.

a Department of Rheumatology, Immunology and Allergology , University Hospital Bern, University of Bern , Bern , Switzerland.

Virus-like particles (VLPs) and nano-particles (NPs) are promising vaccine platforms that have led to the successful development of commercially available vaccines. The 5th international virus-like particle and nano-particle vaccines conference was held in Bern, Switzerland, from the 25th to the 27th of September in 2018. Topics included novel vaccine production techniques, methods to enhance vaccine immunogenicity, and preclinical/clinical efficacy evaluation of vaccine candidates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1557522DOI Listing
January 2019
3 Reads

Vaccination of healthcare workers: is mandatory vaccination needed?

Expert Rev Vaccines 2019 01 10;18(1):5-13. Epub 2018 Dec 10.

d First Department of Pediatrics , National and Kapodistrian University of Athens , Athens , Greece.

Introduction: Vaccinations of healthcare workers (HCWs) aim to directly protect them from occupational acquisition of vaccine-preventable diseases (VPDs) and to indirectly protect their patients and the essential healthcare infrastructure. However, outbreaks due to VPDs continue to challenge healthcare facilities and HCWs are frequently traced as sources of VPDs to vulnerable patients. In addition, HCWs were disproportionately affected during the current measles outbreak in Europe. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1552141DOI Listing
January 2019
1 Read

Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials.

Authors:
M Arbyn L Xu

Expert Rev Vaccines 2018 12 29;17(12):1085-1091. Epub 2018 Nov 29.

a Sciensano , Unit of Cancer Epidemiology/Belgian Cancer Centre , Brussels , Belgium.

Introduction: Recently, the evidence on efficacy and safety of prophylactic HPV vaccines derived from randomized trials was published in the Cochrane database of Systematic reviews. A summary of this Cochrane review is presented below.

Areas Covered: Only trials involving mono-, bi-, and quadrivalent HPV vaccines were included. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2018.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2018.1548282DOI Listing
December 2018
25 Reads

Current approaches toward identifying a correlate of immune protection from tuberculosis.

Expert Rev Vaccines 2019 01 3;18(1):43-59. Epub 2018 Dec 3.

a Jenner Institute, Nuffield Department of Medicine , University of Oxford , Oxford , UK.

Introduction: Mycobacterium tuberculosis kills more people than any other pathogen. Vaccination is the most cost-effective control measure for any infectious disease. Development of an effective vaccine against tuberculosis is hindered by the uncertain predictive value of preclinical animal models, incomplete understanding of protective immunity and lack of validated immune correlates of protection (COP). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1552140DOI Listing
January 2019
14 Reads

Meningococcal B vaccine (4CMenB): the journey from research to real world experience.

Expert Rev Vaccines 2018 12 5;17(12):1111-1121. Epub 2018 Dec 5.

d Vaccine Development Leader , Research and Development Centre , Rockville , MD , USA.

Introduction: Neisseria meningitidis serogroup B (MenB) is the most common cause of bacterial meningitis in many industrialized countries and occurs at any age. The highest incidence is in infants aged <1 year, followed by children and adolescents. Four-component MenB vaccine (4CMenB, Bexsero) is the only MenB vaccine authorized for use in all age-groups. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2018.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2018.1547637DOI Listing
December 2018
37 Reads

Vaccine hesitancy 'outbreaks': using epidemiological modeling of the spread of ideas to understand the effects of vaccine related events on vaccine hesitancy.

Expert Rev Vaccines 2018 12 30;17(12):1063-1070. Epub 2018 Nov 30.

a Cochrane South Africa , South African Medical Research Council , Cape Town , South Africa.

Introduction: Vaccine hesitancy, a growing global problem which is aggravated by vaccine related rumors and (mis)information, has the potential to reverse the gains from vaccination. Areas covered: We describe a selection of vaccine-related events that have made headlines and highlight the effects that these have had on vaccine acceptance. Drawing on these cases, and an adaptation of an epidemiological modeling of the spread of ideas, we propose that vaccine hesitancy can be grouped into two categories: 'baseline' and 'reactive' vaccine hesitancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2018.1549994DOI Listing
December 2018
6 Reads

Developing a vaccine for type 1 diabetes by targeting coxsackievirus B.

Expert Rev Vaccines 2018 12 29;17(12):1071-1083. Epub 2018 Nov 29.

d Children's Hospital , University of Helsinki and Helsinki University Hospital , Helsinki , Finland.

Introduction: Virus infections have long been considered as a possible cause of type 1 diabetes (T1D). One virus group, enteroviruses (EVs), has been studied extensively, and clinical development of a vaccine against T1D-associated EV types has started.

Areas Covered: Epidemiological studies have indicated an association between EVs and T1D. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2018.1548281DOI Listing
December 2018
28 Reads

Development of a measure to assess vaccine confidence among men who have sex with men.

Expert Rev Vaccines 2018 11 15;17(11):1053-1061. Epub 2018 Nov 15.

b Rollins School of Public Health, Hubert Department of Global Health , Emory University , Atlanta , GA , USA.

Background: Recent serogroup C meningococcal disease outbreaks led to meningococcal vaccine recommendations for Southern California men who have sex with men (MSM). Assessment of vaccine confidence is critical to improving vaccine coverage in the context of disease outbreaks wherein immunization(s) are recommended.

Methods: We surveyed MSM using venue-based sampling and began development of the vaccine confidence index (VCI) with 30 survey items corresponding to trust- and safety-related perceptions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2018.1541405DOI Listing
November 2018
17 Reads

Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?

Expert Rev Vaccines 2018 12 15;17(12):1105-1110. Epub 2018 Nov 15.

b Centre for Vaccinology , University Hospitals and University of Geneva , Geneva , Switzerland.

Introduction: The live-attenuated recombinant vesicular stomatitis virus vaccine expressing the glycoprotein (GP) of Zaire Ebola virus (rVSV-ZEBOV) has proven immunogenic in humans and effective in field studies. Yet long-term durability of vaccine responses is unknown.

Areas Covered: We survey the evidence available in the literature for the durability of human responses to rVSV-ZEBOV. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2018.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2018.1546582DOI Listing
December 2018
16 Reads